Dabigatran

Dabigatran and its acyl glucuronides are competitive, direct thrombin inhibitors. Because thrombin (serine protease) enables the conversion of fibrinogen into fibrin during the coagulation cascade, its inhibition prevents the development of a thrombus. Both free and clot-bound thrombin, and thrombin-induced platelet aggregation are inhibited by the active moieties. This lowers the chances of blood clots formation in body and hence reduces the risk of stroke and blood clots in people with Atrial fibrillation.

Brands
Adult Dose
Dose: 75 to 75 mg
Single Dose: 75 (75)
Frequency: 12 hourly
Route: PO
Instructions: For patients with severe renal impairment creatinine clearance (CrCl) 15-30 mL/min. Do not take the missed dose atleast 6 hours before next scheduled dose
Neonatal
Paedriatic
Characteristics
. The Molecular Weight of Dabigatran is 267.70.
Contraindications
Dabigatran is contraindicated in conditions like Bleeding,Hypersensitivity to any component of product.
Effects
The severe or irreversible adverse effects of Dabigatran, which give rise to further complications include Bleeding.Dabigatran produces potentially life-threatening effects which include Bleeding. which are responsible for the discontinuation of Dabigatran therapy.The signs and symptoms that are produced after the acute overdosage of Dabigatran include hemorrhagic complications.The symptomatic adverse reactions produced by Dabigatran are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Anaphylactoid reactions, Abdominal pain, Rashes, Urticaria, Pruritus, Epigastric discomfort, Dyspepsia, Faintness, Hypersensitivity reactions, Chest pain, Esophagitis, Wheezing, Chest tightness, Bleeding, GI ulceration, Swelling of face, Difficulty breathing, Swelling of lips and tongue.
Indications
Dabigatran is primarily indicated in conditions like Stroke, Thromboembolism.
Interactions
No data regarding the interactions of Dabigatran was found.
Interfrence
Dabigatran prolongs the aPTT, ECT and TT
Risks
Drug should not be given to Paediatrics, Pregnant Mothers, patients suffering from Kidney dysfunction, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Cap Store at room temperature, Between 15°C-30°C. Protect from Moisture.
Warnings
Increase risk of bleeding. Renal function should be assessed by calculating creatinine clearance prior to initiation of treatment with Dabigatran.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.